|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT00001930 |
|
Date of registration:
|
03/11/1999 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Treatment of Huntington's Chorea With Amantadine
|
|
Scientific title:
|
NMDA-Receptor Blockade in Huntington's Chorea |
|
Date of first enrolment:
|
April 1999 |
|
Target sample size:
|
25 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00001930 |
|
Study type:
|
Interventional |
|
Study design:
|
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
|
|
Phase:
|
Phase 2
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Key inclusion & exclusion criteria
|
All patients will carry a diagnosis of Huntington's disease confirmed by DNA testing.
Patients will have mild to moderate disease with associated significant chorea.
Ability to comply with study requirements and to report on their condition by telephone.
Males and females between the ages of 18 and 82.
No patients with the presence or history of any medical condition that can reasonably be
expected to subject the patient to unwarranted risk.
No patients with renal impairment (serum creatinine exceeding the upper limit of normal).
No patients with a history of intolerance to previous exposure to amantadine.
No patients with an MMSE of less than 18/30.
No patients receiving other anti-chorea therapies (such as Haldol). Those receiving other
anti-chorea therapies must stop taking these medications for at least 4 weeks prior to the
study to be eligible.
No pregnant women.
Patients must practice effective means of birth control.
Age minimum:
N/A
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Chorea
|
|
Huntington's Disease
|
|
Intervention(s)
|
|
Drug: Amantadine
|
|
Secondary ID(s)
|
|
990098
|
|
99-N-0098
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|